OOIR: Observatory of International Research

Papers

(The TQCC of Translational Neurodegeneration is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	264
Metabolic changes in an animal model of amyotrophic lateral sclerosis evaluated by [18F]-FDG positron emission tomography	255
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	161
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	147
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	120
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	93
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	76
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	76
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	75
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	74
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	69
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	66
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	63
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	63
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	61
Role of dopamine in the pathophysiology of Parkinson’s disease	59
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	58
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	58
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	56
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	55
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	52
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	52
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	49
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	49
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	49

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	48
NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity	47
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta	46
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	44
Inflammasomes in neurodegenerative diseases	42
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	41
Peripheral proteinopathy in neurodegenerative diseases	41
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	40
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	40
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	39
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	38
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	38
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	38
Mitochondrial links between brain aging and Alzheimer’s disease	37
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	37
Multidimensional biomarkers for multiple system atrophy: an update and future directions	36
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	36
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	36
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	36
Perivascular spaces relate to the course and cognition of Huntington’s disease	35
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	35
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	33
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	33
Inhibition of lysine methyltransferase G9a/GLP reinstates long-term synaptic plasticity and synaptic tagging/capture by facilitating protein synthesis in the hippocampal CA1 area of APP/PS1 mouse mode	33
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	32
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	31
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	31
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	31
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	31
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	29
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock	29
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	29
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease	28
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	28
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	27
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy	27
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	27
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	27
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	27